pulmonary large cell neuroendocrine carcinomalung combined large cell neuroendocrine carcinoma+1 moreResearch
The FIRST-NEC GFPC 01-2022 trial protocol outlines an externally controlled trial to evaluate first-line immunochemotherapy for advanced large cell neuroendocrine lung carcinomas. This study aims to enhance treatment strategies for this rare cancer type.
development of an externally controlled trial from a single arm study to assess first line immunochemotherapy in advanced large cell neuroendocrine lung carcinomas a study protocol from the first nec gfpc 01 2022 trial
Original title: “Development of an externally controlled trial from a single-arm study to assess first-line immunochemotherapy in advanced large cell neuroendocrine lung carcinomas: a study protocol from the FIRST-NEC GFPC 01-2022 trial.”